en

Sie sind hier:

Publications

2019

H. Di, H. Elbahesh, M.A. Brinton. Characteristics of human OAS1 isoform proteins. Viruses. 2019. Accepted

 

S. Bergmann, H. Elbahesh. Targeting the proviral host kinase, FAK, limits influenza a virus pathogenesis and NFkB-regulated pro-inflammatory responses. Virology. 2019 Aug;534:54-63. doi: 10.1016/j.virol.2019.05.020. Epub 2019 Jun 1. PubMed PMID: 31176924.

 

R.D. de Vries, N.J. Nieuwkoop, F. Krammer, B. Hu, G.F. Rimmelzwaan. Analysis Of The Vaccine-Induced Influenza B Virus Hemagglutinin-Specific Antibody Dependent Cellular Cytotoxicity Response. Virus Res. 2019 Dec 11:197839.doi:10.1016/

j.virusres.2019. 197839. [Epub ahead of print] PubMed PMID: 31837382.

 

M. van Eijk, M.L.B. Hillaire, G.F. Rimmelzwaan, M.J. Rynkiewicz, M.R. White, K.L. Hartshorn, M. Hessing, P.A. Koolmees, M.H. Tersteeg, M.H. van Es, T. Meijerhof, A. Huckriede, H.P. Haagsman. Enhanced Antiviral Activity of Human Surfactant Protein D by Site-Specific Engineering of the Carbohydrate Recognition Domain. Front Immunol. 2019 Oct 22;10:2476. doi: 10.3389/fimmu.2019.02476. eCollection 2019. PubMed PMID: 31749796; PubMed Central PMCID: PMC6842947.

 

K.A. Frerichs, P.W.C. Bosman, J.F. van Velzen, P.L.A. Fraaij, M.P.G. Koopmans, G.F. Rimmelzwaan, I.S. Nijhof, A.C. Bloem, T. Mutis, S. Zweegman, N.W.C.J. van de Donk. Effect of daratumumab on normal plasma cells, polyclonal immunoglobulin levels, and vaccination responses in extensively pre-treated multiple myeloma patients. Haematologica. 2019 Sep 26. pii: haematol.2019.231860.doi:10.3324 / haematol.2019.231860.[Epub ahead of print] PubMed PMID: 31558675.

 

J.M. Jansen, T. Gerlach, H. Elbahesh, G.F. Rimmelzwaan, G. Saletti. Influenza virus-specific CD4+ and CD8+ T cell-mediated immunity induced by infection and vaccination. J Clin Virol. 2019 Oct;119:44-52. doi: 10.1016/j.jcv.2019.08.009. Epub 2019 Aug 24. Review. PubMed PMID: 31491709.

 

H. Elbahesh, T. Gerlach, G. Saletti, G.F. Rimmelzwaan. Response Modifiers: Tweaking the Immune Response Against Influenza A Virus. Front Immunol. 2019 Apr 12;10:809. doi: 10.3389/fimmu.2019.00809. eCollection 2019. Review. PubMed PMID: 31031778;

PubMed Central PMCID: PMC6473099.

 

B.F. Koel, D.F. Burke, S. van der Vliet, T.M. Bestebroer, G.F. Rimmelzwaan, A.D.M.E. Osterhaus, D.J. Smith, RAM Fouchier. Epistatic interactions can moderate the antigenic effect of substitutions in haemagglutinin of influenza H3N2 virus. J Gen Virol.

2019 May;100(5):773-777. doi: 10.1099/jgv.0.001263. Epub 2019 Apr 24. PubMed PMID: 31017567.

 

E.S. Soilemetzidou, E. De Bruin, M. Franz, O.H.K. Aschenborn, G.F. Rimmelzwaan, R. Van Beek, M. Koopmans, A.D. Greenwood, GÁ Czirják. Diet May Drive Influenza A Virus Exposure in African Mammals. J Infect Dis. 2019 Mar 6. pii: jiz032. doi: 10.1093/infdis/jiz032. [Epub ahead of print] PubMed PMID: 30838397.

 

S. Nüssing, H.F. Koay, S. Sant, T. Loudovaris, S.I. Mannering, M. Lappas, Y. D Udekem, I.E. Konstantinov, S.P. Berzins, G.F. Rimmelzwaan, S.J. Turner, E.B. Clemens, D.I. Godfrey, T.H. Nguyen, K. Kedzierska. Divergent SATB1 expression across human life span and tissue compartments. Immunol Cell Biol. 2019 May;97(5):498-511. doi: 10.1111/imcb.12233. Epub 2019 Feb 25. PubMed PMID: 30803026; PubMed Central PMCID: PMC6618325.

 

R. Meineke, G.F. Rimmelzwaan, H. Elbahesh. Influenza Virus Infections and Cellular Kinases. Viruses. 2019 Feb 20;11(2). pii: E171. doi: 10.3390/v11020171. Review. PubMed PMID: 30791550; PubMed Central PMCID: PMC6410056.

 

T. Gerlach, H. Elbahesh, G. Saletti, G.F. Rimmelzwaan. Recombinant influenza A viruses as vaccine vectors. Expert Rev Vaccines. 2019 Apr;18(4):379-392. doi: 10.1080/14760584.2019.1582338. Epub 2019 Mar 4. PubMed PMID: 30777467.

 

E. Strijbos, M.R. Tannemaat, I. Alleman, R.H.P. de Meel, J.A. Bakker, R. van Beek, F.P. Kroon, G.F. Rimmelzwaan, J.J.G.M. Verschuuren. A prospective, double-blind, randomized, placebo-controlled study on the efficacy and safety of influenza vaccination in myasthenia gravis. Vaccine. 2019 Feb 8;37(7):919-925. doi: 10.1016/j.vaccine.2019.01.007. Epub 2019 Jan 16. PubMed PMID: 30660402.

 

2018

H. Elbahesh, G. Saletti, T. Gerlach, G.F. Rimmelzwaan. Broadly protective influenza vaccines: design and production platforms. Curr Opin Virol. 2019 Feb;34:1-9. doi: 10.1016/j.coviro.2018.11.005. Epub 2018 Nov 27. Review. PubMed PMID: 30497050.

 

B.W.S. Li, M.J.W. de Bruijn, M. Lukkes, M. van Nimwegen, I.M. Bergen, A. KleinJan, C.H. GeurtsvanKessel, A. Andeweg, G.F. Rimmelzwaan, R.W. Hendriks. T cells and ILC2s are major effector cells in influenza-induced exacerbation of allergic airway inflammation in mice. Eur J Immunol. 2019 Jan;49(1):144-156. doi: 10.1002/eji.201747421. Epub 2018 Jun 11. PubMed PMID: 29762870; PubMed Central PMCID: PMC6585726.

 

2016

C.E. van de Sandt, J.H.C.M. Kreijtz, M.M. Geelhoed-Mieras, N.J. Nieuwkoop, M.I. Spronken, D.A.M.C. van de Vijver, RAM Fouchier, A.D.M.E. Osterhaus and G.F. Rimmelzwaan. (2016) Differential recognition of influenza A viruses by M158-66 epitope-specific CD8+ T cells is determined by extra-epitopic amino acid residues. J. Virol. 90(2):1009-22

 

2015

C.E. Van de Sandt, M.L.B. Hillaire, M.M. Geelhoed-Mieras, A.D.M.E. Osterhaus, RAM Fouchier and G.F. Rimmelzwaan. (2015) Human influenza virus specific CD8+ T cell immunity is long-lived.  J. Infect. Dis. 212:81-85

 

2014

J.H.C.M. Kreijtz, M. Goeijenbier, F. Moesker, L. van den Dries, S. Goeijenbier, H. de Gruyter, G. de Mutsert, D.A.M.C. van de Vijver, M. Lehmann, E.C.M. van Gorp, G.F. Rimmelzwaan, G. Sutter and A.D.M.E Osterhaus (2014) Randomised phase I/IIa clinical trial demonstrates safety and immunogenicity of an MVA-based influenza A/H5N1 vaccine in healthy adults. Lancet. Infect. Dis.  14(12):1196-1207

 

2013

B.F. Koel, D.F. Burke, T.M. Bestebroer, S. van der Vliet, G.C. Zondag, G. Vervaet, E. Skepner, N.S. Lewis, M.I. Spronken, C.A. Russell, M.Y. Eropkin, A.C. Hurt, I.G. Barr, J.C. de Jong, G.F. Rimmelzwaan, A.D.M.E. Osterhaus, R.A. Fouchier, D.J. Smith. (2013) Substitutions near the receptor binding site determine major antigenic change during influenza virus evolution. Science 342(6161):976-9

 

M. Richard, E.J.A. Schrauwen, M. de Graaf, T.M. Bestebroer, M. Spronken, S. van Boheemen, D. de Meulder, P. Lexmond, M. Linster, S. Herfst, J.M. van den Brand, D.F. Burke, D.J. Smith, T. Kuiken, G.F. Rimmelzwaan, A.D.M.E. Osterhaus, RAM Fouchier. (2013) Limited airborne transmission of influenza A/H7N9 virus between ferrets. Nature 501(7468):560-3

 

2009

C.H. Geurts van Kessel, M.A.M. Willart, L.S. van Rijt, I.M. Bergen, F. Muskens, A.D.M.E. Osterhaus, R. Hendriks, G.F. Rimmelzwaan and B.N. Lambrecht. (2009) Dendritic cells are crucial for maintenance of tertiary lymphoid structures in the lung of influenza virus-infected mice. J. Exp. Med.  206(11):2339-2349

 

2008

C.H. Geurts van Kessel, M. Willart, L.S. van Rijt, M. Kool, C. Baas, K. Thielemans, H.C. Hoogsteden, A.D.M.E. Osterhaus, G.F. Rimmelzwaan and B.N. Lambrecht. (2008) Clearance of influenza virus from the lung depends on migratory langerin+CD11b- but not plasmacytoid dendritic cells. J. Exp. Med. 205(7):1621-1634

 

2006

G.F. Rimmelzwaan, D. van Riel, G. van Amerongen, M. Baars, R. Fouchier and A. Osterhaus, T. Kuiken. (2006) Influenza A virus (H5N1) infection in domestic cats causes systemic disease with possible novel routes of virus spread within and between hosts. Am. J. Pathol. 168:176-183

 

2004

D.J. Smith, A.S. Lapedes, T.M. Bestebroer, J.C. de Jong, G.F. Rimmelzwaan, A.D.M.E. Osterhaus and RAM Fouchier. (2004) Mapping the antigenic and genetic evolution of influenza virus. Science 305(5682):371-6

 

2003

J. Gog, G.F. Rimmelzwaan, A.D.M.E. Osterhaus and B. Grenfell. (2003) Population dynamics of rapid fixation in CTL escape mutants in influenza A. Proc. Natl. Acad. Sci . USA, 100 (19):11143-11147

Kontakt
Dr. Tina Basler
Tel.:+49 511 953-6141
Fax.:+49 511 953-8675
Diese Seite